TNXP fails in PTSD—phase-3 stopped for futility: https://www.globenewswire.com/news-release/2020/02/05/1980637/0/en/Tonix-Pharmaceuticals-Announces-Outcome-of-Interim-Analysis-for-Phase-3-RECOVERY-Study-of-Tonmya-TNX-102-SL-in-PTSD.html The FDA previous granted and rescinded BTD for this program based on phase-2 data (#msg-147230617). (The stock is currently halted.)